Study details
Enrolling now
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Oregon Health and Science University
NCT IDNCT02342444ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
606
Study length
about 11 years
Ages
15–100
Locations
1 site in OR
What this study is about
This trial is testing whether a lower dose of Lovenox, given twice daily, or a higher dose, given once daily, is better at preventing blood clots in people who are at risk. The goal is to see if one dose reduces the chance of blood clots compared to the other.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Enoxaparin Sodium Injection 30 mg BID
- 2.Receive Enoxaparin Sodium Injection 40 mg QD
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
Cardiovascular Agent [TC] (Antithrombins)
Drug routes
injection